The combination offers a new treatment option for advanced breast cancer patients with ESR1 mutations
Category: Health
Eli Lilly has made a notable advancement in the treatment of advanced breast cancer, as the U.S. Food and Drug Administration (FDA) granted full approval for the combination of Inluriyo (imlunestrant) and Verzenio (abemaciclib) on September 18, 2026. This approval targets adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy.
The combination therapy is particularly relevant as approximately half of patients with ER-positive, HER2-negative metastatic breast cancer develop ESR1 mutations during or after treatment with common hormone-blocking therapies. The FDA's approval is based on the results from the Phase 3 EMBER-3 trial, which demonstrated that the Inluriyo-Verzenio regimen significantly improves patient outcomes.
The EMBER-3 trial enrolled 874 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, previously treated with an aromatase inhibitor, either alone or in conjunction with a CDK4/6 inhibitor. The trial randomized patients to receive either Inluriyo alone, an investigator's choice of endocrine therapy, or the combination of Inluriyo and Verzenio. Among 159 patients with ESR1-mutated tumors included in an exploratory subgroup analysis, the combination therapy was associated with a median progression-free survival (PFS) of 11.1 months compared to just 5.5 months for those receiving Inluriyo alone, translating into a hazard ratio of 0.53 (95% confidence interval, 0.35–0.80).
The Inluriyo-Verzenio combination targets two primary drivers of ER+ breast cancer. Inluriyo works by degrading mutated estrogen receptors, effectively cutting off the signals that promote cancer cell growth. Verzenio, on the other hand, inhibits proteins that regulate cell division, thereby slowing the proliferation of cancer cells. This dual approach is expected to offer a more effective treatment strategy for patients facing resistance to previous therapies.
With this approval, Eli Lilly is positioning Inluriyo as a leading treatment option for patients with ER+, HER2-, ESR1-mutated metastatic breast cancer. Jacob Van Naarden, president of Lilly Oncology, emphasized the importance of this combination, stating, "In less than a year since its approval, Inluriyo is the leading treatment option for people with ER+, HER2-, ESR1-mutated metastatic breast cancer, now reaching over half of all patients starting an oral SERD." He also noted that the regimen does not introduce burdensome monitoring requirements, contrasting sharply with AstraZeneca's recently approved oral SERD, Etcamah, which necessitates blood-based testing for ESR1 mutations.
Looking ahead, the Inluriyo-Verzenio combination is now available in the United States, providing a new avenue for patients who have exhausted other options. The approval is a step forward in addressing the urgent need for effective treatment alternatives in this patient population. As the oncology community continues to monitor the outcomes of this combination therapy, it is unclear how it compares with other treatment strategies, particularly AstraZeneca's Etcamah, which has also entered the competitive oral SERD market.
As with any treatment, the Inluriyo-Verzenio combination comes with its own set of risks. Adverse reactions include severe diarrhea, low white blood cell counts (neutropenia), lung inflammation, liver problems, and blood clots. The prescribing information for Inluriyo includes a warning for embryo-fetal toxicity, indicating potential risks to a developing fetus if used during pregnancy. Continuous monitoring and patient education will be key in managing these risks effectively.
In addition to the current approval, Eli Lilly is also conducting the Phase 3 EMBER-4 trial, which focuses on the use of Inluriyo in the adjuvant setting for patients with early-stage breast cancer at increased risk of recurrence following standard endocrine therapy. Initial results from this trial are anticipated in 2027, potentially broadening the application of Inluriyo beyond metastatic cases.
The recommended dosage for Inluriyo is 400 mg taken orally once daily on an empty stomach, at least two hours before food or one hour after food. Verzenio is administered at a dosage of 150 mg taken twice daily, with or without food. Treatment continues until disease progression or unacceptable toxicity occurs.
As the field of oncology continues to evolve, the approval of Inluriyo and Verzenio marks a promising development for patients struggling with advanced breast cancer. With the emphasis on maximizing treatment efficacy and minimizing unnecessary side effects, this combination offers a strategic approach in the fight against this challenging disease.